| 3.21 0.17 (5.59%) | 11-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.35 | 1-year : | 6.97 |
| Resists | First : | 4.58 | Second : | 5.96 |
| Pivot price | 2.75 |
|||
| Supports | First : | 2.34 | Second : | 1.95 |
| MAs | MA(5) : | 2.83 |
MA(20) : | 2.87  |
| MA(100) : | 2.99 |
MA(250) : | 3.4 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 63.3 |
D(3) : | 38.8 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 8.81 | Low : | 1.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QLGN ] has closed Bollinger Bands are 52.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.08 - 3.1 | 3.1 - 3.11 |
| Low: | 2.72 - 2.73 | 2.73 - 2.75 |
| Close: | 3.02 - 3.04 | 3.04 - 3.06 |
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Tue, 28 Oct 2025
Qualigen Therapeutics Inc. Announces Rebranding to AIxCrypto and Launch of Web3 Initiatives | QLGN Stock News - Quiver Quantitative
Mon, 27 Oct 2025
Qualigen Therapeutics to Rebrand as AIxCrypto After - GlobeNewswire
Fri, 24 Oct 2025
Qualigen Therapeutics (QLGN) Stock Soars 62% After-Hours On Partnership With BitGo To Build Multi-Asset Crypto Treasury - Benzinga
Thu, 23 Oct 2025
Qualigen (NASDAQ: QLGN) chooses BitGo for $30M C10 treasury in top 10 crypto basket - Stock Titan
Mon, 06 Oct 2025
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 383 (K) |
| Shares Short P.Month | 187 (K) |
| EPS | 6.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -171.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | 0.5 |
| PEG Ratio | 0 |
| Price to Book value | -1.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|